10x Genomics, Inc. announced the launch of GEM-X, the next generation of the company's leading single cell technology. The first major overhaul to the Chromium architecture since the 2019 launch of Next GEM technology, GEM-X is built on a new and improved microfluidic chip design, featuring the latest technological advancements and optimized reagents for superior performance and high reliability. The company is now accepting preorders for the first two product launches powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3'v4 and Chromium Single Cell Immune Profiling 5'v3.

These assays are expected to begin shipping this quarter. The new GEM-X technology offers significant performance advantages, including: Substantially increased sensitivity: Detect up to two times more genes compared to on-market Chromium assays to gain a more comprehensive view of cellular heterogeneity; Built to scale: Two-fold increase in cells captured per channel; More cost effective: More than two-fold reduction in cost per cell; Enhanced data quality: Two-fold reduction in multiplet rate enabling high quality data at scale; Maximum sample recovery: Recovery of up to 80% of cells, improving capture efficiency and making it ideal for samples typically yielding few cells, such as tissue biopsies or previously flow sorted cells; Improved assay robustness: Redesigned microfluidics and optimized reagents for faster and more efficient cell partnering. GEM-X is exclusively available for use on Chromium X Series instruments.